Usefulness of serum tryptase level as an independent biomarker for coronary plaque instability in a Chinese population

• Published in: Atherosclerosis Vol. 215; no. 2; pp. 494 - 499
• Main Authors: Xiang, Meixiang, Sun, Jiusong, Lin, Yan, Zhang, Jie, Chen, Han, Yang, Dan, Wang, Jianan, Shi, Guo-Ping
• Format: Journal Article
• Language: English
• Published: Amsterdam Elsevier Ireland Ltd 01.04.2011; Elsevier
• Subjects: Aged; Angina Pectoris - blood; Angina, Unstable - blood; Asian Continental Ancestry Group; atherogenesis; atherosclerosis; Atherosclerosis (general aspects, experimental research); Biological and medical sciences; biomarkers; Biomarkers - blood; Blood and lymphatic vessels; Blood Glucose - analysis; blood serum; Cardiology. Vascular system; Cardiovascular; cholesterol; Chymase; Chymases - blood; Coronary Artery Disease - blood; Coronary Artery Disease - pathology; coronary disease; Coronary heart disease; fasting; Female; glucose; Heart; Humans; linear models; low density lipoprotein; Male; Mast cell; Medical sciences; Middle Aged; myocardial infarction; Myocardial Infarction - blood; patients; Plaque, Atherosclerotic - pathology; Regression Analysis; triacylglycerols; Tryptase; Tryptases - blood; Mast cell; Coronary heart disease; Tryptase; Chymase; Serine endopeptidases; Enzyme; Cardiovascular disease; Vascular disease; Peptidases; Atherosclerosis; Hydrolases; Chinese; Instability
• ISSN: 0021-9150; 1879-1484
• DOI: 10.1016/j.atherosclerosis.2011.01.006

Tryptase and chymase are unique mast cell proteases that are essential in atherogenesis. This study establishes a link between serum tryptase and chymase levels and human coronary heart diseases (CHD) in a cohort of 270 subjects. Serum tryptase levels were significantly higher in patients with substantial CHD than in those without substantial CHD (substantial CHD vs. unsubstantial CHD: 7.81±0.52ng/mL vs. 6.11±0.51ng/mL, P=0.002). After subgrouping the substantial CHD patients into those with acute myocardial infarction (AMI) and those with unstable or stable angina pectoris (UAP or SAP), we demonstrated that serum tryptase levels were nearly doubled in AMI patients as compared with unsubstantial CHD patients (11.13±1.55ng/mL vs. 6.11±0.51ng/mL, P<0.01), and significantly higher than in UAP patients (7.19±0.62ng/mL, P<0.05) or SAP patients (6.80±0.94ng/mL, P<0.05). Although Spearman's correlation test showed that serum tryptase correlated significantly with age (P=0.014) and weakly with fasting glucose (P=0.084), total cholesterol (P=0.071), low-density lipoprotein (P=0.063), and triglyceride (P=0.058), serum tryptase levels remained significantly higher in substantial CHD patients than in unsubstantial CHD patients in a multiple linear regression test after adjusting for all these confounders (P=0.008). Serum chymase levels were also higher in AMI patients (27.64±7.57ng/mL) or UAP patients (24.62±8.06ng/mL) than in SAP patients (15.20±0.81ng/mL) or unsubstantial CHD patients (16.84±0.56ng/mL), although such differences were not statistically significant. Spearman's correlation test revealed that serum chymase levels correlated significantly only with fasting glucose levels (P=0.019), and CHD status did not affect chymase levels before and after adjusting for all confounders. Our observations suggest that serum tryptase is an independent biomarker for coronary plaque stability in this Chinese population.